Please update your Flash Player to view content.

Upcoming Events:

There are no upcoming events.

Bio Pro Classes:

 
Tuesday, 22 Apr 2014
Category: Bio Pro Classes

 
Tuesday, 22 Apr 2014
Category: Bio Pro Classes

 
Thursday, 24 Apr 2014 - Friday, 25 Apr 2014
Category: Bio Pro Classes

 
Thursday, 08 May 2014
Category: Bio Pro Classes

 
Friday, 16 May 2014
Category: Bio Pro Classes

 
Thursday, 22 May 2014
Category: Bio Pro Classes

 
Thursday, 05 Jun 2014 - Friday, 06 Jun 2014
Category: Bio Pro Classes

 
Thursday, 19 Jun 2014 - Friday, 20 Jun 2014
Category: Bio Pro Classes

 
Tuesday, 08 Jul 2014 - Wednesday, 09 Jul 2014
Category: Bio Pro Classes

 
Thursday, 17 Jul 2014 - Friday, 18 Jul 2014
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

 SBIR 101: How to create a competitive SBIR grant application.

 

Dr FarellThis is a must attend event for any entrepreneur trying to pursue SBIR and other forms of government grant funding. Dr. David Farrell will share decades of experience successfully soliciting federal grants (SBIR, STTR, etc.) from the federal government. Unlike other seminars and workshops, Dr. Farrell takes a hands on approach. From teaching you the history of the programs, to actually logging onto the relevant sites and completing registration forms, participants complete the practical steps necessary to jumpstart their submissions.

 

Dr. Farrell's workshop will cover the broadest spectrum of federal programs, including SBIR/STTR programs for the National Science Foundation (NSF), United States Department of Agriculture (USDA), and the Environmental Protection Agency (EPA), with an emphasis on the National Institutes of Health (NIH). In addition, the huge Department of Defense budget will also be explored, including a few little-known pots of money--including: the Congressionally Directed Medical Research Programs (CDMRP), Air Force, Defense Advanced Research Projects Agency (DARPA), Navy, Defense Threat Reduction Agency (DTRA), and Army SBIR/STTR programs and other non-SBIR contract programs.

 

This interactive session will include attendees downloading onto their own laptops each of the subsections of the application forms while Dr. Farrell explains proven strategies for creating competitive applications. This class is focused on overcoming the barriers standing between you and a funded grant.

 

Cost: Members $225, Non-members $300

Date and Time: March 5, 2014 from 1 p.m. to 5:00 p.m.

Location: OTRADI Business Incubator, 4640 SW Macadam, Suite #240

 



News Flash

  • DesignMedix awarded $3 million to develop low-cost, safe malaria drug

    Portland, Oregon, April 15, 2014 — DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.

    “Each year, over 600,000 children under the age of five die of malaria,” said Dr. Sandra Shotwell, president and COO of DesignMedix. “Our new drug will provide another weapon to target this deadly disease, which kills more young children than any other.”

    The drug in development is as a low cost cure for drug-resistant malaria that is as safe as chloroquine, a frontline drug that used for many years until rendered ineffective by drug resistance. Malaria drug resistance — widespread in Africa and Asia — is created by a mutation that causes rapid transport of the drug out of the malaria cells, rendering the drug ineffective. The DesignMedix technology approach creates a new drug that inhibits the transport and overcomes the drug resistance.

    DesignMedix will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company. Three patents have been issued relating to the drug molecules, and DesignMedix has exclusive rights to develop the technology.

    “I am very pleased that NIH has continued to support this work in such a significant way,” said Peyton, who has been working on malaria for more than 15 years.

    Several malaria drugs currently are available from large multinational and Indian drug manufacturers. Most current therapies show drug resistance, and some cost up to tenfold more than the cost projected for DesignMedix’s drug. This drug has high potential to be a good partner drug for existing or pipeline malaria drugs to both overcome drug resistance, and reduce cost. DesignMedix has partnered with Oregon Consultants Inc. (OCI) of Eugene, Oregon to produce material for preclinical and clinical studies.

     About DesignMedix Inc.

    DesignMedix, Inc was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has developed a series of novel, safe and effective drugs that have the potential for low-cost production. For more information please visit http://www.designmedix.com

    The Advanced Technology Phase II award from the National Institutes and Allergy and Infectious Disease (NIAID) is part of the Small Business Technology Transfer Program of the NIH. Research reported in this release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under Award Number R41AI094959. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Bioscience News

  • Last year marked the 20th Anniversary of the BIO International Convention. In her keynote as the newly elected Chair of BIO, Rachel King emphasized BIO members’ commitment to delivering bigger lifesaving and life changing breakthroughs in medicine, agriculture and energy. “Delivering breakthroughs is at the heart of who we are,” King said in her speech, while also noting the need to effectively convey BIO’s message. “As we work to deliver breakthroughs … we must work Read More >

  • A while back, Oregon looked at becoming the first state in the nation to require labeling of foods that contain genetically modified ingredients. Fortunately, the measure was voted dead 71 to 29, and many predicted that the issue would never rise again. However, now a new anti-GMO measure has popped up in “The Beaver State”. A group of local farmers has been successfully able to get a GMO cultivation ban (Measure 15-119) on the ballot for Read More >

  • Starting up a biotech company is risky business. Fortunately, there are bright, determined people willing to take that risk in hopes of developing an innovative medical, industrial or agricultural application. Fortunately, too, there are plenty of local, state, and federal legislators who recognize the value of supporting entrepreneurial innovators. A case in point is Startup America, an alliance of entrepreneurs, corporations, universities, foundations, and other leaders who work together to support high-growth, potentially job producing Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2012. All Rights Reserved.